ALK Negative NSCLC
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations (NCT05157776) | Tongji University | 2021-10-28 |
Track ALK Negative NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.